Possibilities of improving the effectiveness of therapy in patients with chronic cerebral ischemia against the background of COVID-19

Kovalchuk V.V.; Ershova I.I.; Molodovskaya N.V.

doi:https://doi.org/10.17116/jnevro202112103260

Kovalchuk V.V.

Semashko City Hospital No. 38

ORCID: 0000-0002-1004-2162

Ershova I.I.

Semashko City Hospital No. 38

Molodovskaya N.V.

Semashko City Hospital No. 38

Possibilities of improving the effectiveness of therapy in patients with chronic cerebral ischemia against the background of COVID-19

Authors:

Kovalchuk V.V., Ershova I.I., Molodovskaya N.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(3‑2): 60‑66

DOI: 10.17116/jnevro202112103260

Read: 3074 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kovalchuk VV, Ershova II, Molodovskaya NV. Possibilities of improving the effectiveness of therapy in patients with chronic cerebral ischemia against the background of COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(3‑2):60‑66. (In Russ.)
https://doi.org/10.17116/jnevro202112103260

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study the possibility of improving the efficacy of treatment with mexidol in COVID-19 patients with chronic cerebral ischemia (CCI).

MATERIAL AND METHODS

Three hundred and four patients with CCI and COVID-19 were observed, group 1 (n=152) consisted of patients receiving basic therapy and mexidol, group 2 (n=152) received only basic therapy. Mexidol was administered intravenously for 14 days, 500 mg (10 ml) per 400 ml of saline solution, then Mexidol FORTE 250 was administered in a dose of 250 mg 3 times a day for 2 months. The state of cognitive functions (MoCA scale), sleep (Spiegel questionnaire), asthenia (MFI-20 scale), and quality of life (SIP questionnaire) were evaluated. Examinations were performed before treatment, 30 and 75 days after start of treatment.

RESULTS

In group 1, there was a more complete and earlier recovery of the state of cognitive functions (an increase in indicators on the MoCA scale, p<0.01), a regression of asthenia (p<0.05), and normalization of sleep (p<0.01). By the end of the study, there were significantly more patients in group 1 with complete or significant recovery of all quality of life indicators.

CONCLUSION

Long-term sequential therapy with mexidol provides a more complete recovery of impaired functions in patients with CCI and COVID-19.

Keywords:

COVID-19

SARS-CoV-2

chronic cerebral ischemia

asthenia

cognitive disorders

dementia

quality of life

mexidol

Authors:

Kovalchuk V.V.

Semashko City Hospital No. 38

ORCID: 0000-0002-1004-2162

Ershova I.I.

Semashko City Hospital No. 38

Molodovskaya N.V.

Semashko City Hospital No. 38

Received:

10.04.2021

Accepted:

13.04.2021

Close metadata

References:

Kollias A, Kyriakoulis KG, Dimakakos E. et al. Thromboembolic Risk and Anticoagulant Therapy in COVID-19 Patients: Emerging Evidence and Call for Action. British Journal of Haematology. 2020;189:846-847. https://doi.org/10.1111/bjh.16727
Schulkin AV, Filimonova AA. Role of free radical oxidation, hypoxia and their correction in COVID-19 pathogenesis. Terapiya. 2020;5:187-194. (In Russ.). https://doi.org/10.18565/therapy.2020.5.187-194
Khomich OA, Kochetkov SN, Bartosch B, Ivanov AV. Redox biology of respiratory viral infections. Viruses. 2018;10(8):392. https://doi.org/10.3390/v10080392
Liu W, Li H. COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv. 2020 April 27. https://doi.org/10.26434/chemrxiv.11938173.v9
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. https://doi.org/10.1056/NEJMoa2002032
Teplova NV, Grishin DV. Korrektsiya endotelial’noj disfunktsii pri COVID-19. Meditsinskij alfavit. 2020;22:56-59. (In Russ.). https://doi.org/10.33667/2078-5631-2020-22-56-59
Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020;382(20):e60. https://doi.org/10.1056/NEJMc2009787
Lee M-H, Perl DP, Nair G, et al. Microvascular Injury in the Brains of Patients with Covid-19. N Engl J Med. 2021;384(5):481-483. https://doi.org/10.1056/NEJMc2033369
Yaghi S, Ishida K, Torres J, et al. SARS-CoV-2 and Stroke in a New York Healthcare System. Stroke. 2020;51:2002-2011. https://doi.org/10.1161/STROKEAHA.120.030335
Kirova YuI, Shakova FM, Germanova EL, et al. The effect of mexidol on cerebral mitochondriogenesis at a young age and during aging. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(1):62-69. (In Russ.). https://doi.org/10.17116/jnevro202012001162
Voronina TA. Antioxidants/antihypoxants: the missing puzzle piece in effective pathogenetic therapy for COVID-19. Infektsionnye bolezni. 2020;18(2):97-102. (In Russ.). https://doi.org/10.20953/1729-9225-2020-2-97-102
Voronina TA. Geroprotective effects of ethylmethylhydroxypyridine succinate in an experimental. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(4):81-87. (In Russ.). https://doi.org/10.17116/jnevro202012004181
Ivanova GE, Melnikova EV, Levin OS, et al. Current issues in the rehabilitation of stroke patients against the background of a new coronavirus infection (COVID-19). Resolution of the Council of Experts. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8):81-87. (In Russ.). https://doi.org/10.17116/jnevro202012008281
Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. Psychosom Res. 1995;39(3):315-325. https://doi.org/10.1016/0022-3999(94)00125-o
Poluektov MG. Somnologiya i meditsina sna. Natsional’noe rukovodstvo. M.: Medforum; 2016. (In Russ.).
Folstein M, Folstein S, McHugh P. Mini-mental state. J Psych Res. 1975; 12(3):189-198. https://doi.org/10.1016/0022-3956(75)90026-6
Nasreddine Z, Phillips N, Bacdirian V, et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatr Soc. 2005;53(4):695-699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
Bergner M, Bobbitt R, Carter W, Gilson B. The Sickness Impact Profile: Development and Final Revision of a Health Status Measure. Medical Care. 1981;19(8):787-805. https://doi.org/10.1097/00005650-198108000-00001
Kovalchuk VV, Khafizova TL, Galkin AS. The use of neurometabolic treatment in the complex rehabilitation in poststroke patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;11:61-66. (In Russ.).
Pavelkina VF. The clinico-pathogenetic aspects of intoxication syndrome development at a grippe and the possibilities of its correction. Vestnik novykh meditsinskikh tekhnologij. 2008;15(4):58-62. (In Russ.).